How can MSC production scale without compromising therapeutic efficacy? RoosterBio is proud to sponsor the Cell & Gene Live Event, Scaling Next-Gen MSC Therapies Without Scaling Risk, on September 10th at 11:00 AM (ET). As more programs move toward late-stage clinical trials and commercialization, developers must produce enough high-quality MSCs to meet growing demand while maintaining potency, consistency, and manufacturability.

This panel discussion is hosted by Cell & Gene’s Chief Editor, Erin Harris, and features experts Miguel Forte, MD, PhD, of Kiji Therapeutics; Silviu Itescu, MD, of Mesoblast; and Edward Ahn, PhD, of MEDIPOST. We invite you to join and gain practical insights into what developers should prioritize today to improve their products’ chances of clinical and commercial success tomorrow.